Trial Profile
Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for Treatment of IDA in CKD Patients on Hemodialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FACT
- Sponsors AMAG Pharmaceuticals
- 25 Feb 2019 Primary endpoint (mean change in hemoglobin from baseline to week 5) has been met, according to the results published in the Clinical Nephrology.
- 25 Feb 2019 Long-term safety and efficacy (noninferiority versus iron sucrose) results published in the Clinical Nephrology.
- 06 Feb 2015 Status changed from recruiting to active, no longer recruiting according to United Kingdom Clinical Research Network record.